S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   163.53 (+2.05%)
MSFT   336.99 (+0.11%)
FB   334.23 (-1.12%)
GOOGL   2,912.02 (+0.05%)
AMZN   3,580.42 (+0.53%)
TSLA   1,164.77 (+2.44%)
NVDA   331.93 (-0.55%)
BABA   130.07 (-1.17%)
NIO   40.87 (+1.01%)
CGC   10.90 (-1.45%)
AMD   163.79 (+1.16%)
GE   96.56 (-1.87%)
MU   86.39 (+0.29%)
T   23.17 (-3.01%)
F   19.58 (-0.46%)
DIS   146.13 (-1.14%)
ACB   6.44 (+0.00%)
AMC   35.77 (-2.90%)
PFE   53.18 (+1.49%)
BA   196.60 (-0.96%)
S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   163.53 (+2.05%)
MSFT   336.99 (+0.11%)
FB   334.23 (-1.12%)
GOOGL   2,912.02 (+0.05%)
AMZN   3,580.42 (+0.53%)
TSLA   1,164.77 (+2.44%)
NVDA   331.93 (-0.55%)
BABA   130.07 (-1.17%)
NIO   40.87 (+1.01%)
CGC   10.90 (-1.45%)
AMD   163.79 (+1.16%)
GE   96.56 (-1.87%)
MU   86.39 (+0.29%)
T   23.17 (-3.01%)
F   19.58 (-0.46%)
DIS   146.13 (-1.14%)
ACB   6.44 (+0.00%)
AMC   35.77 (-2.90%)
PFE   53.18 (+1.49%)
BA   196.60 (-0.96%)
S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   163.53 (+2.05%)
MSFT   336.99 (+0.11%)
FB   334.23 (-1.12%)
GOOGL   2,912.02 (+0.05%)
AMZN   3,580.42 (+0.53%)
TSLA   1,164.77 (+2.44%)
NVDA   331.93 (-0.55%)
BABA   130.07 (-1.17%)
NIO   40.87 (+1.01%)
CGC   10.90 (-1.45%)
AMD   163.79 (+1.16%)
GE   96.56 (-1.87%)
MU   86.39 (+0.29%)
T   23.17 (-3.01%)
F   19.58 (-0.46%)
DIS   146.13 (-1.14%)
ACB   6.44 (+0.00%)
AMC   35.77 (-2.90%)
PFE   53.18 (+1.49%)
BA   196.60 (-0.96%)
S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   163.53 (+2.05%)
MSFT   336.99 (+0.11%)
FB   334.23 (-1.12%)
GOOGL   2,912.02 (+0.05%)
AMZN   3,580.42 (+0.53%)
TSLA   1,164.77 (+2.44%)
NVDA   331.93 (-0.55%)
BABA   130.07 (-1.17%)
NIO   40.87 (+1.01%)
CGC   10.90 (-1.45%)
AMD   163.79 (+1.16%)
GE   96.56 (-1.87%)
MU   86.39 (+0.29%)
T   23.17 (-3.01%)
F   19.58 (-0.46%)
DIS   146.13 (-1.14%)
ACB   6.44 (+0.00%)
AMC   35.77 (-2.90%)
PFE   53.18 (+1.49%)
BA   196.60 (-0.96%)
NASDAQ:CDTX

Cidara Therapeutics Price Target, Predictions & Analyst Ratings

$1.44
+0.01 (+0.70%)
(As of 11/30/2021 09:58 AM ET)
Add
Compare
Today's Range
$1.43
$1.46
50-Day Range
$1.40
$2.35
52-Week Range
$1.31
$3.15
Volume
12,318 shs
Average Volume
697,794 shs
Market Capitalization
$96.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13

Cidara Therapeutics (NASDAQ:CDTX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Strong Buy
Based on 2 Analyst Ratings

Analyst Price Target Consensus

$7.13
394.79% Upside

High PT$8.00
Average PT$7.13
Low PT$6.25
TypeCurrent
11/30/20 to 11/30/21
1 Month Ago
10/31/20 to 10/31/21
3 Months Ago
9/1/20 to 9/1/21
1 Year Ago
12/1/19 to 11/30/20
Consensus Rating
Strong Buy
Buy
Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.13$8.08$9.50$6.65
Price Target Upside394.79% Upside259.79% Upside319.43% Upside108.86% Upside
Get Cidara Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cidara Therapeutics (NASDAQ:CDTX) vs. Its Competitors

TypeCidara TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.50
2.72
2.56
Consensus RatingStrong BuyBuyBuy
Price Target Upside394.79% Upside180.89% Upside12.58% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
398
72.10%
Underperform Votes
154
27.90%
Avg. Outperform Votes
176
67.43%
Avg. Underperform Votes
85
32.57%
Avg. Outperform Votes
834
69.44%
Avg. Underperform Votes
367
30.56%

Cidara Therapeutics (NASDAQ:CDTX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/22/2021Aegis
Lower Price TargetBuy$9.00 ➝ $8.00+250.88%
9/22/2021WBB Securities
UpgradeBuy ➝ Strong-Buy$6.25+192.06%
11/6/2020Maxim Group
Jason McCarthy
Reiterated RatingBuy$10.00+331.03%
8/26/2020Citigroup
Lower Price TargetBuy$6.00 ➝ $5.00+37.36%
8/14/2020Needham & Company LLC
Alan Carr
Initiated CoverageBuy$6.00+57.48%
8/13/2020Oppenheimer
Reiterated RatingBuy$6.00+58.73%
9/4/2019BTIG Research
Reiterated RatingBuy$7.00+197.87%
9/3/2019Wedbush
R. Driscoll
UpgradeNeutral ➝ Outperform$2.00 ➝ $4.00+70.21%
6/12/2019Cantor Fitzgerald
Lower Price TargetOverweight ➝ Reduce$15.00 ➝ $8.00+422.87%
(Data available from 11/30/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Cidara Therapeutics (NASDAQ:CDTX) Analyst Ratings Frequently Asked Questions

What is Cidara Therapeutics's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Cidara Therapeutics stock is Strong Buy based on the current 1 buy rating and 1 strong buy rating for CDTX. The average twelve-month price target for Cidara Therapeutics is $7.13 with a high price target of $8.00 and a low price target of $6.25. Learn more on CDTX's analyst rating history

Do Wall Street analysts like Cidara Therapeutics more than its competitors?

Analysts like Cidara Therapeutics stock more than the stock of other Medical companies. The consensus rating for Cidara Therapeutics is Strong Buy while the average consensus rating for medical companies is Buy. Learn more on how CDTX compares to other companies

Do MarketBeat users like Cidara Therapeutics more than its competitors?

MarketBeat users like Cidara Therapeutics stock more than the stock of other Medical companies. 72.10% of MarketBeat users gave Cidara Therapeutics an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users.

Is Cidara Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, Cidara Therapeutics's stock had 1 upgrade by analysts.

Does Cidara Therapeutics's stock price have much upside?

According to analysts, Cidara Therapeutics's stock has a predicted upside of 222.40% based on their 12-month price targets.

What analysts cover Cidara Therapeutics?

Cidara Therapeutics has been rated by Aegis, and WBB Securities in the past 90 days.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.